Heterogeneity of treatment effect by baseline risk of mortality in critically ill patients: re-analysis of three recent sepsis and ARDS ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-05-03

AUTHORS

Shalini Santhakumaran, Anthony Gordon, A. Toby Prevost, Cecilia O’Kane, Daniel F. McAuley, Manu Shankar-Hari

ABSTRACT

BackgroundRandomised controlled trials (RCTs) enrolling patients with sepsis or acute respiratory distress syndrome (ARDS) generate heterogeneous trial populations. Non-random variation in the treatment effect of an intervention due to differences in the baseline risk of death between patients in a population represents one form of heterogeneity of treatment effect (HTE). We assessed whether HTE in two sepsis and one ARDS RCTs could explain indeterminate trial results and inform future trial design.MethodsWe assessed HTE for vasopressin, hydrocortisone and levosimendan in sepsis and simvastatin in ARDS patients, on 28-day mortality, using the total Acute Physiology And Chronic Health Evaluation II (APACHE II) score as the baseline risk measurement, comparing above (high) and below (low) the median score. Secondary risk measures were the acute physiology component of APACHE II and predicted risk of mortality using the APACHE II score. HTE was quantified both in additive (difference in risk difference (RD)) and multiplicative (ratio of relative risks (RR)) scales using estimated treatment differences from a logistic regression model with treatment risk as the interaction term.ResultsThe ratio of the odds of death in the highest APACHE II quartile was 4.9 to 7.4 times compared to the lowest quartile, across the three trials. We did not observe HTE for vasopressin, hydrocortisone and levosimendan in the two sepsis trials. In the HARP-2 trial, simvastatin reduced mortality in the low APACHE II group and increased mortality in the high APACHE II group (difference in RD = 0.34 (0.12, 0.55) (p = 0.02); ratio of RR 3.57 (1.77, 7.17) (p < 0.001). The HTE patterns were inconsistent across the secondary risk measures. The sensitivity analyses of HTE effects for vasopressin, hydrocortisone and levosimendan were consistent with the main analyses and attenuated for simvastatin.ConclusionsWe assessed HTE in three recent ICU RCTs, using multivariable baseline risk of death models. There was considerable within-trial variation in the baseline risk of death. We observed potential HTE for simvastatin in ARDS, but no evidence of HTE for vasopressin, hydrocortisone or levosimendan in the two sepsis trials. Our findings could be explained either by true lack of HTE (no benefit of vasopressin, hydrocortisone or levosimendan vs comparator for any patient subgroups) or by lack of power to detect HTE. Our results require validation using similar trial databases. More... »

PAGES

156

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s13054-019-2446-1

DOI

http://dx.doi.org/10.1186/s13054-019-2446-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1113904984

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/31053084


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "APACHE", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anti-Inflammatory Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cardiotonic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Critical Illness", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Guideline Adherence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hospital Mortality", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hydrocortisone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hydroxymethylglutaryl-CoA Reductase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Intensive Care Units", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Respiratory Distress Syndrome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sepsis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Simendan", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Simvastatin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vasoconstrictor Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vasopressins", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Imperial Clinical Trials Unit, School of Public Health, Imperial College London, W12 7RH, London, UK", 
          "id": "http://www.grid.ac/institutes/grid.7445.2", 
          "name": [
            "Imperial Clinical Trials Unit, School of Public Health, Imperial College London, W12 7RH, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Santhakumaran", 
        "givenName": "Shalini", 
        "id": "sg:person.0656110035.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0656110035.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Section of Anaesthetics, Pain Medicine and Intensive Care, Imperial College London, W2 1NY, London, UK", 
          "id": "http://www.grid.ac/institutes/grid.7445.2", 
          "name": [
            "Section of Anaesthetics, Pain Medicine and Intensive Care, Imperial College London, W2 1NY, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gordon", 
        "givenName": "Anthony", 
        "id": "sg:person.01114060235.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01114060235.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Imperial Clinical Trials Unit, School of Public Health, Imperial College London, W12 7RH, London, UK", 
          "id": "http://www.grid.ac/institutes/grid.7445.2", 
          "name": [
            "Imperial Clinical Trials Unit, School of Public Health, Imperial College London, W12 7RH, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Prevost", 
        "givenName": "A. Toby", 
        "id": "sg:person.01121673270.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01121673270.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre for Experimental Medicine, Wellcome-Wolfson Institute for Experimental Medicine, BT9 7AE, Belfast, UK", 
          "id": "http://www.grid.ac/institutes/grid.4777.3", 
          "name": [
            "Centre for Experimental Medicine, Wellcome-Wolfson Institute for Experimental Medicine, BT9 7AE, Belfast, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "O\u2019Kane", 
        "givenName": "Cecilia", 
        "id": "sg:person.0706061252.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706061252.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Regional Intensive Care Unit, Royal Victoria Hospital, BT12 6BA, Belfast, UK", 
          "id": "http://www.grid.ac/institutes/grid.416232.0", 
          "name": [
            "Centre for Experimental Medicine, Wellcome-Wolfson Institute for Experimental Medicine, BT9 7AE, Belfast, UK", 
            "Regional Intensive Care Unit, Royal Victoria Hospital, BT12 6BA, Belfast, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McAuley", 
        "givenName": "Daniel F.", 
        "id": "sg:person.013052706317.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013052706317.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peter Gorer Department of Immunobiology, School of Immunology & Microbial Sciences, King\u2019s College London, SE1 9RT, London, UK", 
          "id": "http://www.grid.ac/institutes/grid.13097.3c", 
          "name": [
            "Department of Intensive Care Medicine, St Thomas\u2019 Hospital, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, Westminster Bridge Road, SE1 7EH, London, UK", 
            "Peter Gorer Department of Immunobiology, School of Immunology & Microbial Sciences, King\u2019s College London, SE1 9RT, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shankar-Hari", 
        "givenName": "Manu", 
        "id": "sg:person.01242172705.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01242172705.25"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/s13063-017-1978-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1086115341", 
          "https://doi.org/10.1186/s13063-017-1978-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1745-6215-11-85", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045446161", 
          "https://doi.org/10.1186/1745-6215-11-85"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-05-03", 
    "datePublishedReg": "2019-05-03", 
    "description": "BackgroundRandomised controlled trials (RCTs) enrolling patients with sepsis or acute respiratory distress syndrome (ARDS) generate heterogeneous trial populations. Non-random variation in the treatment effect of an intervention due to differences in the baseline risk of death between patients in a population represents one form of heterogeneity of treatment effect (HTE). We assessed whether HTE in two sepsis and one ARDS RCTs could explain indeterminate trial results and inform future trial design.MethodsWe assessed HTE for vasopressin, hydrocortisone and levosimendan in sepsis and simvastatin in ARDS patients, on 28-day mortality, using the total Acute Physiology And Chronic Health Evaluation II (APACHE II) score as the baseline risk measurement, comparing above (high) and below (low) the median score. Secondary risk measures were the acute physiology component of APACHE II and predicted risk of mortality using the APACHE II score. HTE was quantified both in additive (difference in risk difference (RD)) and multiplicative (ratio of relative risks (RR)) scales using estimated treatment differences from a logistic regression model with treatment risk as the interaction term.ResultsThe ratio of the odds of death in the highest APACHE II quartile was 4.9 to 7.4 times compared to the lowest quartile, across the three trials. We did not observe HTE for vasopressin, hydrocortisone and levosimendan in the two sepsis trials. In the HARP-2 trial, simvastatin reduced mortality in the low APACHE II group and increased mortality in the high APACHE II group (difference in RD\u2009=\u20090.34 (0.12, 0.55) (p\u2009=\u20090.02); ratio of RR 3.57 (1.77, 7.17) (p\u2009<\u20090.001). The HTE patterns were inconsistent across the secondary risk measures. The sensitivity analyses of HTE effects for vasopressin, hydrocortisone and levosimendan were consistent with the main analyses and attenuated for simvastatin.ConclusionsWe assessed HTE in three recent ICU RCTs, using multivariable baseline risk of death models. There was considerable within-trial variation in the baseline risk of death. We observed potential HTE for simvastatin in ARDS, but no evidence of HTE for vasopressin, hydrocortisone or levosimendan in the two sepsis trials. Our findings could be explained either by true lack of HTE (no benefit of vasopressin, hydrocortisone or levosimendan vs comparator for any patient subgroups) or by lack of power to detect HTE. Our results require validation using similar trial databases.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s13054-019-2446-1", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.6954007", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.5148217", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.6798288", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.5125396", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.9712263", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.9712273", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.9714325", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2784459", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1117766", 
        "issn": [
          "1364-8535", 
          "1466-609X"
        ], 
        "name": "Critical Care", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "23"
      }
    ], 
    "keywords": [
      "acute respiratory distress syndrome", 
      "II score", 
      "Chronic Health Evaluation II score", 
      "II group", 
      "APACHE II score", 
      "respiratory distress syndrome", 
      "odds of death", 
      "future trial design", 
      "risk of mortality", 
      "treatment effects", 
      "logistic regression models", 
      "Acute Physiology", 
      "APACHE II", 
      "sepsis trials", 
      "ARDS patients", 
      "distress syndrome", 
      "trial population", 
      "baseline risk", 
      "treatment risks", 
      "trial design", 
      "sepsis", 
      "median score", 
      "patients", 
      "mortality", 
      "trial results", 
      "physiology component", 
      "trials", 
      "treatment differences", 
      "levosimendan", 
      "simvastatin", 
      "hydrocortisone", 
      "scores", 
      "risk", 
      "vasopressin", 
      "regression models", 
      "death", 
      "RCTs", 
      "group", 
      "syndrome", 
      "population", 
      "quartile", 
      "MethodsWe", 
      "odds", 
      "intervention", 
      "differences", 
      "interaction terms", 
      "HTE", 
      "effect", 
      "physiology", 
      "measures", 
      "heterogeneity", 
      "non-random variation", 
      "ratio", 
      "time", 
      "scale", 
      "results", 
      "components", 
      "form", 
      "measurements", 
      "model", 
      "forms of heterogeneity", 
      "variation", 
      "terms", 
      "design", 
      "risk measures", 
      "risk measurement"
    ], 
    "name": "Heterogeneity of treatment effect by baseline risk of mortality in critically ill patients: re-analysis of three recent sepsis and ARDS randomised controlled trials", 
    "pagination": "156", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1113904984"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s13054-019-2446-1"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "31053084"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s13054-019-2446-1", 
      "https://app.dimensions.ai/details/publication/pub.1113904984"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T16:03", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_822.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s13054-019-2446-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13054-019-2446-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13054-019-2446-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13054-019-2446-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13054-019-2446-1'


 

This table displays all metadata directly associated to this object as RDF triples.

295 TRIPLES      21 PREDICATES      117 URIs      106 LITERALS      30 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s13054-019-2446-1 schema:about N028bc109e33c41278db78e3a2c152d22
2 N042ae00ef8594faf92dc52f79f629dfb
3 N096eb0a0ae4b40e9b764ef6160d4151a
4 N0aabbaab54e442539fd142cdb6b92083
5 N2a9376e68a634cf0b0ff6ac13c441dc6
6 N2c426349a2f64013b71c4a07eda0f43c
7 N5114c964557b44f19be76b85d8df62d2
8 N580d0804c60b4295bfdebe51cb62649e
9 N66076cdbc263467fae51b085acb4c7e2
10 N6e9094e45e1140e68df2ee58ec9b4ad2
11 N7b2f12900fd74f88a964242a01e0c7c4
12 N82e3ffff73d749e5bfe92ebb16b891e0
13 N9457dcd0c69043fabbb5c30c8301d06d
14 Nab1a32bf334f4f9caabf35f8189979aa
15 Nae7f7b2045f14a3b93a50914472f32d1
16 Nb07c7bc0965f42158bd1df905262e572
17 Nc53e59c804d1416d8c2c09c3471358e3
18 Nc5b4b3d5f95248e289a12272b3c51d89
19 Ncc847f86afae40759ccdbf3625edf853
20 Nd085d0f625bf40e38c17e5684e4d6e10
21 Ne768e0f603684d658d77e8317558cf41
22 Need8eca7cd9b456186180b0dd072509e
23 Nf8f74b6877f5496b8954d94a63eda157
24 anzsrc-for:11
25 anzsrc-for:1103
26 anzsrc-for:1117
27 schema:author N15667a246bc749fb90be02f2c181ec5c
28 schema:citation sg:pub.10.1186/1745-6215-11-85
29 sg:pub.10.1186/s13063-017-1978-4
30 schema:datePublished 2019-05-03
31 schema:datePublishedReg 2019-05-03
32 schema:description BackgroundRandomised controlled trials (RCTs) enrolling patients with sepsis or acute respiratory distress syndrome (ARDS) generate heterogeneous trial populations. Non-random variation in the treatment effect of an intervention due to differences in the baseline risk of death between patients in a population represents one form of heterogeneity of treatment effect (HTE). We assessed whether HTE in two sepsis and one ARDS RCTs could explain indeterminate trial results and inform future trial design.MethodsWe assessed HTE for vasopressin, hydrocortisone and levosimendan in sepsis and simvastatin in ARDS patients, on 28-day mortality, using the total Acute Physiology And Chronic Health Evaluation II (APACHE II) score as the baseline risk measurement, comparing above (high) and below (low) the median score. Secondary risk measures were the acute physiology component of APACHE II and predicted risk of mortality using the APACHE II score. HTE was quantified both in additive (difference in risk difference (RD)) and multiplicative (ratio of relative risks (RR)) scales using estimated treatment differences from a logistic regression model with treatment risk as the interaction term.ResultsThe ratio of the odds of death in the highest APACHE II quartile was 4.9 to 7.4 times compared to the lowest quartile, across the three trials. We did not observe HTE for vasopressin, hydrocortisone and levosimendan in the two sepsis trials. In the HARP-2 trial, simvastatin reduced mortality in the low APACHE II group and increased mortality in the high APACHE II group (difference in RD = 0.34 (0.12, 0.55) (p = 0.02); ratio of RR 3.57 (1.77, 7.17) (p < 0.001). The HTE patterns were inconsistent across the secondary risk measures. The sensitivity analyses of HTE effects for vasopressin, hydrocortisone and levosimendan were consistent with the main analyses and attenuated for simvastatin.ConclusionsWe assessed HTE in three recent ICU RCTs, using multivariable baseline risk of death models. There was considerable within-trial variation in the baseline risk of death. We observed potential HTE for simvastatin in ARDS, but no evidence of HTE for vasopressin, hydrocortisone or levosimendan in the two sepsis trials. Our findings could be explained either by true lack of HTE (no benefit of vasopressin, hydrocortisone or levosimendan vs comparator for any patient subgroups) or by lack of power to detect HTE. Our results require validation using similar trial databases.
33 schema:genre article
34 schema:isAccessibleForFree true
35 schema:isPartOf N060a13ba2a934b2bb4c460f660204308
36 N14d5186e206945a78af7a4ac99e96a53
37 sg:journal.1117766
38 schema:keywords APACHE II
39 APACHE II score
40 ARDS patients
41 Acute Physiology
42 Chronic Health Evaluation II score
43 HTE
44 II group
45 II score
46 MethodsWe
47 RCTs
48 acute respiratory distress syndrome
49 baseline risk
50 components
51 death
52 design
53 differences
54 distress syndrome
55 effect
56 form
57 forms of heterogeneity
58 future trial design
59 group
60 heterogeneity
61 hydrocortisone
62 interaction terms
63 intervention
64 levosimendan
65 logistic regression models
66 measurements
67 measures
68 median score
69 model
70 mortality
71 non-random variation
72 odds
73 odds of death
74 patients
75 physiology
76 physiology component
77 population
78 quartile
79 ratio
80 regression models
81 respiratory distress syndrome
82 results
83 risk
84 risk measurement
85 risk measures
86 risk of mortality
87 scale
88 scores
89 sepsis
90 sepsis trials
91 simvastatin
92 syndrome
93 terms
94 time
95 treatment differences
96 treatment effects
97 treatment risks
98 trial design
99 trial population
100 trial results
101 trials
102 variation
103 vasopressin
104 schema:name Heterogeneity of treatment effect by baseline risk of mortality in critically ill patients: re-analysis of three recent sepsis and ARDS randomised controlled trials
105 schema:pagination 156
106 schema:productId N7b5fe73ca6004963a770dfb029b4d3cc
107 N87f1f77c0836426680c53c4d2f12b82b
108 N987166b553d8480e9dbfc6ce7720b53f
109 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113904984
110 https://doi.org/10.1186/s13054-019-2446-1
111 schema:sdDatePublished 2022-09-02T16:03
112 schema:sdLicense https://scigraph.springernature.com/explorer/license/
113 schema:sdPublisher N4cc8f476fd8b4f778b6e462ce6203dce
114 schema:url https://doi.org/10.1186/s13054-019-2446-1
115 sgo:license sg:explorer/license/
116 sgo:sdDataset articles
117 rdf:type schema:ScholarlyArticle
118 N028bc109e33c41278db78e3a2c152d22 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Sepsis
120 rdf:type schema:DefinedTerm
121 N042ae00ef8594faf92dc52f79f629dfb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Humans
123 rdf:type schema:DefinedTerm
124 N060a13ba2a934b2bb4c460f660204308 schema:issueNumber 1
125 rdf:type schema:PublicationIssue
126 N096eb0a0ae4b40e9b764ef6160d4151a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name APACHE
128 rdf:type schema:DefinedTerm
129 N0aabbaab54e442539fd142cdb6b92083 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Simvastatin
131 rdf:type schema:DefinedTerm
132 N14d5186e206945a78af7a4ac99e96a53 schema:volumeNumber 23
133 rdf:type schema:PublicationVolume
134 N15667a246bc749fb90be02f2c181ec5c rdf:first sg:person.0656110035.10
135 rdf:rest Na6d5731c080846e6aa23425d84d6def3
136 N2a9376e68a634cf0b0ff6ac13c441dc6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Respiratory Distress Syndrome
138 rdf:type schema:DefinedTerm
139 N2c426349a2f64013b71c4a07eda0f43c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Hospital Mortality
141 rdf:type schema:DefinedTerm
142 N4cc8f476fd8b4f778b6e462ce6203dce schema:name Springer Nature - SN SciGraph project
143 rdf:type schema:Organization
144 N5114c964557b44f19be76b85d8df62d2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Anti-Inflammatory Agents
146 rdf:type schema:DefinedTerm
147 N580d0804c60b4295bfdebe51cb62649e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Critical Illness
149 rdf:type schema:DefinedTerm
150 N66076cdbc263467fae51b085acb4c7e2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Vasoconstrictor Agents
152 rdf:type schema:DefinedTerm
153 N6e9094e45e1140e68df2ee58ec9b4ad2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Hydrocortisone
155 rdf:type schema:DefinedTerm
156 N7b2f12900fd74f88a964242a01e0c7c4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Cardiotonic Agents
158 rdf:type schema:DefinedTerm
159 N7b5fe73ca6004963a770dfb029b4d3cc schema:name doi
160 schema:value 10.1186/s13054-019-2446-1
161 rdf:type schema:PropertyValue
162 N82e3ffff73d749e5bfe92ebb16b891e0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Treatment Outcome
164 rdf:type schema:DefinedTerm
165 N87f1f77c0836426680c53c4d2f12b82b schema:name pubmed_id
166 schema:value 31053084
167 rdf:type schema:PropertyValue
168 N9457dcd0c69043fabbb5c30c8301d06d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Guideline Adherence
170 rdf:type schema:DefinedTerm
171 N987166b553d8480e9dbfc6ce7720b53f schema:name dimensions_id
172 schema:value pub.1113904984
173 rdf:type schema:PropertyValue
174 Na6d5731c080846e6aa23425d84d6def3 rdf:first sg:person.01114060235.79
175 rdf:rest Nc5c2f8797ea74624beae7d41fd91caf8
176 Nab1a32bf334f4f9caabf35f8189979aa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Vasopressins
178 rdf:type schema:DefinedTerm
179 Nae7f7b2045f14a3b93a50914472f32d1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Male
181 rdf:type schema:DefinedTerm
182 Nb07c7bc0965f42158bd1df905262e572 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Middle Aged
184 rdf:type schema:DefinedTerm
185 Nc53e59c804d1416d8c2c09c3471358e3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Intensive Care Units
187 rdf:type schema:DefinedTerm
188 Nc5b4b3d5f95248e289a12272b3c51d89 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Simendan
190 rdf:type schema:DefinedTerm
191 Nc5c2f8797ea74624beae7d41fd91caf8 rdf:first sg:person.01121673270.37
192 rdf:rest Ne3ba8e4c8b96488dbbb9da8cf68fb9a9
193 Ncc847f86afae40759ccdbf3625edf853 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name Adult
195 rdf:type schema:DefinedTerm
196 Nd085d0f625bf40e38c17e5684e4d6e10 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
197 schema:name Female
198 rdf:type schema:DefinedTerm
199 Ndab4acf5602e49f4950ef4ae06146e7c rdf:first sg:person.013052706317.18
200 rdf:rest Neb5709c8e53045718080b087deb25ec5
201 Ne3ba8e4c8b96488dbbb9da8cf68fb9a9 rdf:first sg:person.0706061252.72
202 rdf:rest Ndab4acf5602e49f4950ef4ae06146e7c
203 Ne768e0f603684d658d77e8317558cf41 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
204 schema:name Randomized Controlled Trials as Topic
205 rdf:type schema:DefinedTerm
206 Neb5709c8e53045718080b087deb25ec5 rdf:first sg:person.01242172705.25
207 rdf:rest rdf:nil
208 Need8eca7cd9b456186180b0dd072509e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
209 schema:name Aged
210 rdf:type schema:DefinedTerm
211 Nf8f74b6877f5496b8954d94a63eda157 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
212 schema:name Hydroxymethylglutaryl-CoA Reductase Inhibitors
213 rdf:type schema:DefinedTerm
214 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
215 schema:name Medical and Health Sciences
216 rdf:type schema:DefinedTerm
217 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
218 schema:name Clinical Sciences
219 rdf:type schema:DefinedTerm
220 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
221 schema:name Public Health and Health Services
222 rdf:type schema:DefinedTerm
223 sg:grant.2784459 http://pending.schema.org/fundedItem sg:pub.10.1186/s13054-019-2446-1
224 rdf:type schema:MonetaryGrant
225 sg:grant.5125396 http://pending.schema.org/fundedItem sg:pub.10.1186/s13054-019-2446-1
226 rdf:type schema:MonetaryGrant
227 sg:grant.5148217 http://pending.schema.org/fundedItem sg:pub.10.1186/s13054-019-2446-1
228 rdf:type schema:MonetaryGrant
229 sg:grant.6798288 http://pending.schema.org/fundedItem sg:pub.10.1186/s13054-019-2446-1
230 rdf:type schema:MonetaryGrant
231 sg:grant.6954007 http://pending.schema.org/fundedItem sg:pub.10.1186/s13054-019-2446-1
232 rdf:type schema:MonetaryGrant
233 sg:grant.9712263 http://pending.schema.org/fundedItem sg:pub.10.1186/s13054-019-2446-1
234 rdf:type schema:MonetaryGrant
235 sg:grant.9712273 http://pending.schema.org/fundedItem sg:pub.10.1186/s13054-019-2446-1
236 rdf:type schema:MonetaryGrant
237 sg:grant.9714325 http://pending.schema.org/fundedItem sg:pub.10.1186/s13054-019-2446-1
238 rdf:type schema:MonetaryGrant
239 sg:journal.1117766 schema:issn 1364-8535
240 1466-609X
241 schema:name Critical Care
242 schema:publisher Springer Nature
243 rdf:type schema:Periodical
244 sg:person.01114060235.79 schema:affiliation grid-institutes:grid.7445.2
245 schema:familyName Gordon
246 schema:givenName Anthony
247 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01114060235.79
248 rdf:type schema:Person
249 sg:person.01121673270.37 schema:affiliation grid-institutes:grid.7445.2
250 schema:familyName Prevost
251 schema:givenName A. Toby
252 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01121673270.37
253 rdf:type schema:Person
254 sg:person.01242172705.25 schema:affiliation grid-institutes:grid.13097.3c
255 schema:familyName Shankar-Hari
256 schema:givenName Manu
257 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01242172705.25
258 rdf:type schema:Person
259 sg:person.013052706317.18 schema:affiliation grid-institutes:grid.416232.0
260 schema:familyName McAuley
261 schema:givenName Daniel F.
262 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013052706317.18
263 rdf:type schema:Person
264 sg:person.0656110035.10 schema:affiliation grid-institutes:grid.7445.2
265 schema:familyName Santhakumaran
266 schema:givenName Shalini
267 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0656110035.10
268 rdf:type schema:Person
269 sg:person.0706061252.72 schema:affiliation grid-institutes:grid.4777.3
270 schema:familyName O’Kane
271 schema:givenName Cecilia
272 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706061252.72
273 rdf:type schema:Person
274 sg:pub.10.1186/1745-6215-11-85 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045446161
275 https://doi.org/10.1186/1745-6215-11-85
276 rdf:type schema:CreativeWork
277 sg:pub.10.1186/s13063-017-1978-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1086115341
278 https://doi.org/10.1186/s13063-017-1978-4
279 rdf:type schema:CreativeWork
280 grid-institutes:grid.13097.3c schema:alternateName Peter Gorer Department of Immunobiology, School of Immunology & Microbial Sciences, King’s College London, SE1 9RT, London, UK
281 schema:name Department of Intensive Care Medicine, St Thomas’ Hospital, Guy’s and St Thomas’ NHS Foundation Trust, Westminster Bridge Road, SE1 7EH, London, UK
282 Peter Gorer Department of Immunobiology, School of Immunology & Microbial Sciences, King’s College London, SE1 9RT, London, UK
283 rdf:type schema:Organization
284 grid-institutes:grid.416232.0 schema:alternateName Regional Intensive Care Unit, Royal Victoria Hospital, BT12 6BA, Belfast, UK
285 schema:name Centre for Experimental Medicine, Wellcome-Wolfson Institute for Experimental Medicine, BT9 7AE, Belfast, UK
286 Regional Intensive Care Unit, Royal Victoria Hospital, BT12 6BA, Belfast, UK
287 rdf:type schema:Organization
288 grid-institutes:grid.4777.3 schema:alternateName Centre for Experimental Medicine, Wellcome-Wolfson Institute for Experimental Medicine, BT9 7AE, Belfast, UK
289 schema:name Centre for Experimental Medicine, Wellcome-Wolfson Institute for Experimental Medicine, BT9 7AE, Belfast, UK
290 rdf:type schema:Organization
291 grid-institutes:grid.7445.2 schema:alternateName Imperial Clinical Trials Unit, School of Public Health, Imperial College London, W12 7RH, London, UK
292 Section of Anaesthetics, Pain Medicine and Intensive Care, Imperial College London, W2 1NY, London, UK
293 schema:name Imperial Clinical Trials Unit, School of Public Health, Imperial College London, W12 7RH, London, UK
294 Section of Anaesthetics, Pain Medicine and Intensive Care, Imperial College London, W2 1NY, London, UK
295 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...